Piper Sandler Issues Positive Forecast for Cardiff Oncology (NASDAQ:CRDF) Stock Price

Cardiff Oncology (NASDAQ:CRDF) had its target price increased by Piper Sandler from $7.00 to $10.00 in a research note released on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts have also issued research reports about the company. Craig Hallum began coverage on Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright dropped their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, November 8th.

Cardiff Oncology Stock Up 19.9 %

Shares of Cardiff Oncology stock opened at $3.92 on Friday. The company has a fifty day moving average of $2.89 and a 200-day moving average of $2.62. Cardiff Oncology has a 52-week low of $1.27 and a 52-week high of $6.42.

Insider Activity at Cardiff Oncology

In related news, Director Gary W. Pace bought 350,115 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was purchased at an average cost of $2.60 per share, with a total value of $910,299.00. Following the transaction, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.80% of the stock is currently owned by company insiders.

Institutional Trading of Cardiff Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. raised its position in shares of Cardiff Oncology by 380.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after acquiring an additional 962,940 shares in the last quarter. Geode Capital Management LLC grew its stake in Cardiff Oncology by 1.9% in the third quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock worth $2,479,000 after purchasing an additional 17,557 shares during the period. State Street Corp grew its stake in Cardiff Oncology by 3.4% in the third quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after purchasing an additional 27,628 shares during the period. MAI Capital Management raised its holdings in Cardiff Oncology by 0.7% in the third quarter. MAI Capital Management now owns 663,363 shares of the company’s stock worth $1,771,000 after purchasing an additional 4,569 shares in the last quarter. Finally, Blair William & Co. IL lifted its position in Cardiff Oncology by 32.2% during the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock valued at $505,000 after buying an additional 55,450 shares during the period. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.